Ganciclovir
Brand Names: Zirgan
Methodology & AI Transparency ⓘ
Ganciclovir Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage zirgan: is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older.
- 2 Real-world patient consensus: Zero-PHI community consensus: 85% favorable across 9 logged regimens (Zirgan).
- 3 Typical cash cost range: Dispensing cost comparison spans $185.00 mail/discount cash up to $453.25 uninsured retail (federal NADAC $91.2378).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Ganciclovir: blurred vision (60%), application-site irritation (20%), nausea (8.3%).
Ask our AI Specialists anything about Ganciclovir
Ganciclovir Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage zirgan: is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ZIRGAN is a nucleoside analog antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ( 1 )
12.1 Mechanism of Action ZIRGAN is an antiviral drug . Ganciclovir operates pharmacologically within the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class (RxNorm 388052; NDC 24208-535, 42023-173), engaging target pathways across 500 mg/10mL Injection, Powder, Lyophilized, for Solution; 1.5 mg/g Gel dosing.
Clinical clearance of Ganciclovir (Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor) relies on systemic clearance of ganciclovir integrates hepatic phase ii conjugation with renal filtration with a Elimination kinetics span 8 to 19 hours per Ganciclovir clinical pharmacology half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Ganciclovir (500 mg/10mL Injection, Powder, Lyophilized, for Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after ganciclovir administration.
FDA clinical labeling for Ganciclovir restricts administration in confirmed ige-mediated allergy or cutaneous reaction to ganciclovir (ganciclovir) components; uncompensated hepatic or renal insufficiency incompatible with ganciclovir (500 mg/10ml injection, powder, lyophilized, for solution) clearance across 500 mg/10mL Injection, Powder, Lyophilized, for Solution, 1.5 mg/g Gel, with self-reported patient tracking dominated by blurred vision (60% of reports), application-site irritation (20% of reports), nausea (8.3% of reports).
Reconcile eGFR-adjusted medications before escalating Ganciclovir in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Ganciclovir dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Ganciclovir (Ganciclovir) components
- Uncompensated hepatic or renal insufficiency incompatible with Ganciclovir (500 mg/10mL Injection, Powder, Lyophilized, for Solution) clearance
Logged Side-Effect Incidence (9 Reports)
Ganciclovir Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ganciclovir)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease Kidney function did not impact staying on track with medication, quantifiable CMV DNAemia, or prophylaxis discontinuation in the letermovir group; however, staying on track with medication was lower, and quantifiable CMV... American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40701254 ↗ |
| Can This Approach Help? Inside the Latest Research on [Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on Further, the incidence of neutropenia during the treatment observation period was lower in the maribavir arm than in the valganciclovir arm (22.2% vs 55.6% ). Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi • 2025-12-14 • Phase III Randomized Trial | N = 18 | 88/100 | PMID 41486656 ↗ |
| Can This Approach Help? Inside the Latest Research on Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Baseline maribavir resistance was rare. The Journal of infectious diseases • 2024-02-14 • Phase III Randomized Trial | N = 34 | 82/100 | PMID 37506264 ↗ |
| Can This Approach Help? Inside the Latest Research on Effectiveness and tolerability of post solid organ transplant patients with CMV MBV-treated patients had 10-15% lower tolerability issues; over 7 in 10 demonstrated treatment effectiveness in this real-world analysis. Expert review of anti-infective therapy • 2025-08-15 • Phase III Randomized Trial | N = 29 | 82/100 | PMID 40478680 ↗ |
| New Insights on Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized: What a 241-Participant Study Found After 3-8 weeks of therapy, maribavir resistance emerged earlier and more frequently than ganciclovir resistance but was usually treatable using alternative therapy. The Journal of infectious diseases • 2025-03-17 • Phase III Randomized Trial | N = 241 | 82/100 | PMID 39302855 ↗ |
Ganciclovir Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $91.2378/unit (~$2737.13/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 9 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Ganciclovir Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ganciclovir RxNorm Concept ID | 388052 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $91.2378 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (9 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ganciclovir Patient Community, Cohort Filters & Dosage Logs
Cross-verified Ganciclovir (cytomegalovirus nucleoside analog dna polymerase inhibitor) monograph synthesizing RxNorm 388052, openFDA FAERS signals, and $185.00–$453.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ganciclovir community threads and patient logs by age, biological sex, dosage, and treatment duration.